| Staging systems of hepatocellular carcinoma: a review of literature M Maida, E Orlando, C Cammà, G Cabibbo World Journal of Gastroenterology: WJG 20 (15), 4141, 2014 | 152 | 2014 |
| MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease S Petta, L Valenti, F Marra, S Grimaudo, C Tripodo, E Bugianesi, ... Journal of hepatology 64 (3), 682-690, 2016 | 127 | 2016 |
| Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study F Mocciaro, S Renna, A Orlando, G Rizzuto, E Sinagra, E Orlando, ... Journal of Crohn's and Colitis 6 (6), 681-686, 2012 | 74 | 2012 |
| Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease A Orlando, FW Guglielmi, M Cottone, E Orlando, C Romano, E Sinagra Digestive and Liver Disease 45 (12), 986-991, 2013 | 64 | 2013 |
| Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response G Cabibbo, M Maida, C Genco, N Alessi, M Peralta, G Butera, M Galia, ... PLoS One 8 (7), e70016, 2013 | 47 | 2013 |
| Metabolic factors and chronic hepatitis C: a complex interplay FS Macaluso, M Maida, MG Minissale, T Li Vigni, S Attardo, E Orlando, ... BioMed Research International 2013, 2013 | 44 | 2013 |
| Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience FS Macaluso, S Renna, M Maida, M Dimarco, C Sapienza, M Affronti, ... Scandinavian journal of gastroenterology 52 (9), 981-987, 2017 | 31 | 2017 |
| Could JC virus provoke metastasis in colon cancer? E Sinagra, D Raimondo, E Gallo, M Stella, M Cottone, A Orlando, F Rossi, ... World Journal of Gastroenterology: WJG 20 (42), 15745, 2014 | 26 | 2014 |
| The addition of an immunosuppressant after loss of response to anti-TNFα monotherapy in inflammatory bowel disease: a 2-year study FS Macaluso, C Sapienza, M Ventimiglia, S Renna, G Rizzuto, R Orlando, ... Inflammatory Bowel Diseases 24 (2), 394-401, 2018 | 19 | 2018 |
| HCV/HBV coinfection: The dark side of DAAs treatment? S Madonia, E Orlando, G Madonia, M Cannizzaro Liver International 37 (7), 2017 | 18 | 2017 |
| a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis S Renna, E Orlando, FS Macaluso, M Maida, M Affronti, M Giunta, ... Alimentary Pharmacology & Therapeutics 44 (3), 310-311, 2016 | 11 | 2016 |
| Metabolic disorders across hepatocellular carcinoma in Italy F Morisco, M Guarino, MR Valvano, F Auriemma, F Farinati, EG Giannini, ... Liver International 38 (11), 2028-2039, 2018 | 10 | 2018 |
| Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants FS Macaluso, M Maida, S Renna, E Orlando, M Affronti, C Sapienza, ... Digestive and Liver Disease 49 (2), 157-162, 2017 | 8 | 2017 |
| Selective use of combination therapy in patients with infliximab-resistant inflammatory bowel disease: data from a tertiary referral center A Orlando, S Renna, G Rizzuto, E Orlando, M Affronti, M Cottone Clinical Gastroenterology and Hepatology 14 (6), 914, 2016 | 8 | 2016 |
| Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study A Orlando, S Renna, F Mocciaro, M Cappello, M Giunta, M Mendolaro, ... Digestive and Liver Disease 48 (11), 1314-1317, 2016 | 7 | 2016 |
| Herpes zoster eruption during vedolizumab therapy: a simple coincidence or more? GM Garbo, FS Macaluso, S Renna, E Orlando, A Orlando Inflammatory Bowel Diseases 26 (6), e51-e52, 2020 | 3 | 2020 |
| should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? S Madonia, E Orlando, B Stagno, M Cannizzaro, G Madonia, M Cottone Alimentary Pharmacology & Therapeutics 43 (9), 1021-1022, 2016 | 2 | 2016 |
| Personalized sorafenib therapy for hepatocellular carcinoma G Cabibbo, M Iavarone, M Maida, A di Martino, E Orlando, C Zavaglia, ... Digestive and Liver Disease 45, e371, 2013 | 2 | 2013 |
| An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: We are willing to take a risk of serious adverse events for a doubtful benefit? E Sinagra, C Romano, R Virdone, E Orlando, M Cottone, A Orlando Journal of Crohn's and Colitis 6 (9), 954-955, 2012 | 2 | 2012 |
| switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. FS Macaluso, V Criscuoli, E Orlando, G Rizzuto, S Renna, M Cottone, ... Alimentary Pharmacology & Therapeutics 43 (9), 1019-1020, 2016 | 1 | 2016 |
Filippo MocciaroUOC Gastroenterologia ed Endoscopia Digestiva, ARNAS Civico-Di Cristina-BenfratelliEmail verificata su arnascivico.it
